Lars Edvinsson is a Professor and senior consultant at Lund University/Hospital in Internal Medicine, MD, PhD, Chairman of the Swedish Migraine Society on the board of EHF, and immediate past president of IHS. He was invited to be a professor at Copenhagen University in "Receptor Regulation in Cerebrovascular and Cardiovascular Diseases" in 2008, and is currently Director of the Glostrup Research Park, Copenhagen. In 2012, he received a Lifetime Achievement award from American Headache colleagues (Stowe, VT) and Honorary Dr Hon Causa in Szeged, Hungary. He has a long history in studies of cerebral circulation, innervation, receptors, and function. In 1984, he was the first to describe CGRP in cranial vessels and the trigeminal ganglion, showed the release of CGRP in conjunction with migraine and cluster headache attacks, and has been instrumental in the development of novel CGRP receptor antagonists. His current work is centered on finding the localization of the CGRP family of receptors in cranial structures and CNS to illustrate the possible sites of action of novel CGRP-acting drugs. The work also involves studies of other possible migraine candidates such as PACAP and 5-HT subtype receptor expressions, as well as studies of their interactions and functional roles.
Lars Edvinsson is a Professor and senior consultant at Lund University/Hospital in Internal Medicine, MD, PhD, Chairman of the Swedish Migraine Society on the board of EHF, and immediate past president of IHS. He was invited to be a professor at Copenhagen University in "Receptor Regulation in Cerebrovascular and Cardiovascular Diseases" in 2008, and is currently Director of the Glostrup Research Park, Copenhagen. In 2012, he received a Lifetime Achievement award from American Headache colleagues (Stowe, VT) and Honorary Dr Hon Causa in Szeged, Hungary. He has a long history in studies of cerebral circulation, innervation, receptors, and function. In 1984, he was the first to describe CGRP in cranial vessels and the trigeminal ganglion, showed the release of CGRP in conjunction with migraine and cluster headache attacks, and has been instrumental in the development of novel CGRP receptor antagonists. His current work is centered on finding the localization of the CGRP family of receptors in cranial structures and CNS to illustrate the possible sites of action of novel CGRP-acting drugs. The work also involves studies of other possible migraine candidates such as PACAP and 5-HT subtype receptor expressions, as well as studies of their interactions and functional roles.